A modern approach to dyslipidemia
AJ Berberich, RA Hegele - Endocrine reviews, 2022 - academic.oup.com
Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …
commonly encountered in clinical practice and often have implications for cardiovascular …
Causes and consequences of hypertriglyceridemia
CJ Packard, J Boren, MR Taskinen - Frontiers in endocrinology, 2020 - frontiersin.org
Elevations in plasma triglyceride are the result of overproduction and impaired clearance of
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …
[HTML][HTML] Triglyceride lowering with pemafibrate to reduce cardiovascular risk
A Das Pradhan, RJ Glynn, JC Fruchart… - … England Journal of …, 2022 - Mass Medical Soc
Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …
whether reductions in these levels would lower the incidence of cardiovascular events is …
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
V Dubois, J Eeckhoute, P Lefebvre… - The Journal of clinical …, 2017 - Am Soc Clin Investig
Peroxisome proliferator–activated receptors (PPARs) regulate energy metabolism and
hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non …
hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non …
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
MR Taskinen, J Borén - Atherosclerosis, 2015 - Elsevier
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for
patients with type 2 diabetes, despite recent significant advances in management strategies …
patients with type 2 diabetes, despite recent significant advances in management strategies …
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
MJ Chapman, HN Ginsberg, P Amarenco… - European heart …, 2011 - academic.oup.com
Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …
Overproduction of very low–density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
M Adiels, SO Olofsson, MR Taskinen… - … , and vascular biology, 2008 - Am Heart Assoc
Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2
diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia …
diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia …
Sorting out the roles of PPARα in energy metabolism and vascular homeostasis
P Lefebvre, G Chinetti, JC Fruchart… - The Journal of clinical …, 2006 - Am Soc Clin Investig
PPARα is a nuclear receptor that regulates liver and skeletal muscle lipid metabolism as
well as glucose homeostasis. Acting as a molecular sensor of endogenous fatty acids (FAs) …
well as glucose homeostasis. Acting as a molecular sensor of endogenous fatty acids (FAs) …
[HTML][HTML] Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis
L Alvarez-Jimenez, F Morales-Palomo… - European journal of …, 2023 - Elsevier
Aims To update the evidence about the diabetogenic effect of statins. Methods We searched
for randomized-controlled trials reporting the effects of statin therapy on glycosylated …
for randomized-controlled trials reporting the effects of statin therapy on glycosylated …
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
MJ Chapman, W Le Goff, M Guerin… - European heart …, 2010 - academic.oup.com
Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major
cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual …
cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual …